Cargando…

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes

Hypomethylating agents (HMAs) are effective therapies in myelodysplastic syndromes (MDS), but allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure MDS. According to the current literature, it is difficult to confirm whether HMAs bridging therapy is beneficial for MD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Liu, Jia, Menglu, Sun, Ling, Tian, Wenliang, Tang, Ping, Jiang, Zhongxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505317/ https://www.ncbi.nlm.nih.gov/pubmed/33866494 http://dx.doi.org/10.1007/s10238-021-00712-0

Ejemplares similares

P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)
por: Runzhi, MA, et al.
Publicado: (2023)

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis
por: Du, Yufeng, et al.
Publicado: (2023)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
por: Kungwankiattichai, Smith, et al.
Publicado: (2022)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
por: Beauvais, David, et al.
Publicado: (2022)

Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation
por: Kook, Min-Ha, et al.
Publicado: (2014)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome: A case report
por: Zhang, Ying, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Motivation for physical activity before and after allogeneic hematopoietic stem cell transplantation
por: Nakano, Kimiko, et al.
Publicado: (2023)

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
por: Haas, Marion, et al.
Publicado: (2020)

Treatment of Crohn’s disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review
por: Hu, Changmei, et al.
Publicado: (2014)

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
por: Lindholm, C., et al.
Publicado: (2022)

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
por: Schuler, Esther, et al.
Publicado: (2020)

Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report
por: Ai, Yuan, et al.
Publicado: (2020)

Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Chen, Yi-Bin, et al.
Publicado: (2009)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Cardiopulmonary Exercise Test With Comorbidity Index Before Allogeneic Hematopoietic Stem Cell Transplantation
por: Yeon, Sang Hoon, et al.
Publicado: (2022)

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation
por: Hemsing, Anette Lodvir, et al.
Publicado: (2021)

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation
por: Hou, Chang, et al.
Publicado: (2021)

Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2022)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

P738: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY
por: Kotselyabina, Polina, et al.
Publicado: (2023)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant
por: Campbell, Angela P., et al.
Publicado: (2015)

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
por: Ciotti, Giulia, et al.
Publicado: (2022)

Clinical Analysis of Bloodstream Infections During Agranulocytosis After Allogeneic Hematopoietic Stem Cell Transplantation
por: Cao, Weijie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8rn2tfj4kqa4odvti7obairu88